www.eximbankindia.com Recruitment 2012 Export-Import Bank of India : Administrative Officer (Secretarial Work)

[muthukalee]

Name of the organisation : Export-Import Bank of India ( eximbankindia.com )
Name of the post : Recruitment for Administrative Officers (Secretarial Work) in 2012

Applications are invited for the position of Administrative Officers (Secretarial Work) in Mumbai

Export-Import Bank of India, an all India financial institution engaged in financing, facilitating and promoting India's international trade, having a network of 16 offices in India and overseas and Learning Centres in Bangalore, Ahmedabad and Pune invites applications from experienced secretarial and administrative professionals, for the positions of Administrative Officers, in Mumbai, meeting the following eligibility criteria :

http://www.eximbankindia.com
http://www.eximbankindia.com/ao2012.pdf

The job profile will include, inter alia, handling verbal and written communication, maintaining up to date filing, mailing list, handling mail, maintaining record of inward/outward mail, managing and channeling information, organising, prioritising executive time, travel arrangements, preparation of letters, faxes, notes etc.

The candidate should be a graduate in any discipline from a recognized university and should also be conversant in computers with an ability to adapt to changing technology.

The candidate should be fluent in spoken English and should possess excellent communication skills. Knowledge of foreign languages will be an added advantage.

The candidate should have experience of minimum 10 years, in secretarial functions.

Total Number of Posts : 7

Candidate’s age should not be lower than 35 years, or higher than 45 years (as on December 1, 2011 ). The candidate must be a citizen of India.

Selected candidates will be appointed as Administrative Officers on probation for a period of one year in Grade/Scale JM I in the Bank through a selection process, with a salary of Rs. 25,000/- p.m. (approximately). Besides salary, other perquisites include Gratuity, Pension, LTC, conveyance allowance, medical facilities, and other staff welfare facilities, as may be applicable.

Only those who satisfy the required qualification and experience need apply. Applications that do not meet with the requirements will be rejected and no correspondence in this regard will be entertained. Applications in any other format will not be considered by the Bank. Canvassing in any form will be a disqualification.

The Selection Process will comprise of Written Test and Personal Interview. The date and timing of the Written Test will be advised to the shortlisted candidates at a later date. Candidates who are shortlisted based on the performance in the Written Test will be called for Personal Interview.

Please send your application containing the above-mentioned particulars within 15 days from the date of this advertisement, to the following address.
The General Manager-HRM,
Export-Import Bank of India
Centre One Building, Floor 21,
World Trade Centre Complex,Cuffe Parade,
Mumbai 400005

[Guest-IJT]

Name : DR NITIN SHETTY
Email : nitinshetty AT yahoo.com
Designation / Skillset : VICE PRESIDENT PRECLINICAL DIVISION

Resume :
EDUCATIONAL QUALIFICATION Degree University Year Of Passing Subject Offered %Age/Grade Obtained
B.Sc. Bombay 1987 Zoology 62
M.Sc. (Research) Bombay 1991
Biological Sciences (Drug Safety) A+ Ph.D.Bombay 1996
Biological Sciences (Drug Safety) -
TITLE OF THESIS : -
M.Sc. Research : Toxicity Studies of Famotidine in Mice and Rats
Ph.D. : Toxicity Studies of Ketorolac Thromethamine in Mice
and Rats
GUIDEING PROFESSOR : -
Dr (Smt.) Rohini Sivabalan
Professor, Dept. Of Biological Sciences
Ramnarian Ruia College, Matunga,
Bombay – 400 019, Maharastra, INDIA.
PROFESSIONAL EXPERIENCE :
2009 to date
- Presently working with Vimta Laboratory Limited a Contract Research Organization, as Vice President and heading the Pre-clinical Division, a strategic business unit based in Genome Valley, Hyderabad, AP, India.
- Prime responsibilities Include recommendation of strategic plans to identify core areas of business relevance to support preclinical drug discovery services and facilitate expand business to become a leading provider of innovative drug discovery and development biology solutions.
- Develop and implement a virtual research concept together with the preclinical department heads through creation of core competence in all required activities within drug discovery and drug development services and create a specific niche area in the contract research market to be differentiated from competition.
- Put forth plans for infrastructure and laboratories for pharmacology, Drug Metabolism and Pharmacokinetics (DMPK), Safety Pharmacology, Toxicology and Animal house.
- Creating multidisciplinary divisions within preclinical and setting up scientific expertise and talent pools with varied technical competencies for the revenant divisions.
Activities and Responsibilities :-
- Has identified areas within preclinical to be major business drivers and to support the companies ambitious plans to offer drug discovery solutions to domestic and global drug discovery pharmaceutical and biotechnological companies. Create in-house capabilities to be a “One-Stop-Shop” and establish screening tools to facilitate lead identification / optimization thro’ ADME, in vitro cytotoxicity and genotoxicity SAR. Fast track PK and toxicity studies for go-no go decision making and assist in identification of IND-candidate and potential NDA-candidate. Evolve competencies to carry out IND-enabling DMPK, Safety Pharmacology and Toxicity studies to plan first-in-man studies.
- Have established within the preclinical division core competencies in the area of pharmacology, DMPK, safety pharmacology and toxicology.
- Proposed capital and revenue budgets including man power requirement, involved in identification, negotiations and placing orders of sophisticated instruments and equipments to support various preclinical activities. Assistance in procurement of data processing and documentation, hardware’s and soft-wares for data compilation, statistics, image transfer and maintenance of animal house records (animal records, air conditioning/ventilation, lighting,) metabolic cages, cages as per international specification, humidity and temperature recorders and data-logging systems.
- Have established group of scientists and associates within pharmacology to develop and standardize in vitro and in vivo models to screen NCEs in the areas of Pain & inflammation, metabolic disorders and cardiovascular diseases.
- Involved in establishing and developing cell based assays for assessment of absorption and permeability using CaCo2, MDCK cells and Parallel Artificial Membrane Permeability Assay (PAMPA), hERG channel assays for determining potential on NCEs to elicit QT prolongation, cytotoxicity assays for identification of target organ toxicity using battery of cell lines, Cytochrome 450 assays to determine the CYP inhibition and induction potential of NCEs, assays in multi-species microsomes to determine/identify metabolites. P- Glycoprotein efflux/ inhibition studies and Skin permeability assay (Franz Diffusion cells) using various skin matrices viz. Cadaver skin, human skin, infant pig skin, hairless mice & rat skin.
- Has extended directions for development of models for metabolic stability and identification studies using liver microsomes of mouse, rat, dog, monkey and human, rat and human hepatocytes. Physico-chemical studies to determine solubility studies for NCE and LogP and LogD. Plasma / Whole blood studies in mouse ,rat, dog and human and Plasma / Whole blood stability in mouse, rat, dog and human
- Have established a team of scientists to undertake rodent and non-rodent DMPK studies and have established a set-up to undertake bio-analytical assays using different analytical tools (HPLC, LC MS MS, GC) and also assist in method development, validation and transfer. The bioanalytical team is currently equipped to identify and quantify metabolites and also supports in analysis of formulation for the DMPK, Safety Pharmacology and toxicity studies.
- Have guided the group to establish and standardize methods for establishing core battery and supplementary assays for assessment of safety pharmacology parameters including telemetry studies in conscience dogs to assess cardiovascular parameters, CNS parameters in rodents, respiratory parameters in conscience rodents, assessment of GIT irritability, drug-drug interactions and has actively involved and supported the preclinical safety assessment group to established and validate models for in vitro and in vivo genotoxicity, models for in vivo phototoxicity assessment and have put in active process to initiate short and long term IND and NDA enabling toxicity studies in rodents and dogs.
- A dedicated team has been selected to undertake pharmacopeial assay for biotechnological and bio-similar products. Has helped in standardizing the pharmacopeia specific quality control screening models and abnormal toxicity tests.
- Involved in designing and establishment of a state of the art animal house to facilitate uninterrupted animal supply for various activities. The animal is designed considering international regulatory prerequisites and guidelines and has been contrived to house species such as multi strain rats, mice, rabbits, Guinea pigs and dogs. Few of the areas are specifically designed with individual ventilated caging systems to house genetically modified animals such as ob ob and db db mice, nude and SCID mice, ZDF rats and Zucker fa fa rats. Currently in process of preparing the program description for AAALAC accreditation. Involved in interaction with governmental bodies for relevant rodent and non-rodent facility certification. Identified sources for procurement of quality animals, feeds, bedding materials, testing of water, feed, bedding etc. from within the country and overseas. Has established expertise to screen animals for different pathogens using specific Elisa kits. A strategy for periodic health and environment monitoring is in place and specific SOPs are in place.
- Currently a team of 52 members including Sr Managers, Managers, Group leaders, Sr. Scientists, Scientists, Research Associates and Research Assistants with varied relevant competencies has been screened and selected and are involved in setting up and standardizing various models. Around 25 more people has been selected and are expected to join the group in the coming few months.
- A 8-member Institutional Animal Ethics Committee to institutionalize and monitor the indiscriminate use of animals and regulate/monitor the functioning of animal-house activity has been formed and has proposed quarterly meetings to take-up/resolve issues and approvals of study protocols.
- Prepared an extensive annual business plan and also extending training to the business development group to show-case Vimta's preclinical capabilities and services.
- As a test facility manager involved in establishing appropriated quality systems in critical functional areas of preclinical division. A quality audit unit (QAU) has been formed to carry out internal quality checks and approve SOPs, protocols and final reports. Draft quality manuals, SOPs and raw data formats have been prepared and are under quality audits. Has been instrumental in incorporating proper quality system in the functional laboratory for core and critical functional areas in the preclinical division.
- Has delegated scientist into preparation of generic study designs and protocols for various preclinical studies. Has trained dedicated project managers within the group for day-day interaction with the clients and sponsors and are involved in preparing client specific protocols, schedules and follow-ups of queries.
- Based the study designs, facility running cost and working costs including man-hours for each specific protocols, pricing strategy is in place for all the drug discovery services offered.
- Involved in administrative activities and has been involved in putting forth working policies for the preclinical division. Recommendations of trainings to different levels of staff taken to be equipped with the most recent and advanced tools in respective areas. Proposal made to facilitate scientists attending conferences and scientific meeting to be abreast with the recent scientific development and also show-case Vimta's preclinical service capabilities to different companies attending the meeting and creating a proper business links.
- Has put forth various plans and screening strategies for other therapeutic areas viz. antibacterial screening to the executive board and management increase service portfolio and expand preclinical business opportunities to be the major future business driver in the company .
1998 to 2009
- Sr. Associate Director-Drug Discovery Research, Head – Preclinical Safety & Bioefficacy Assessment Division & Animal House, at Wockhardt Research Centre, Aurangabad, Maharashtra.
- Principal assignment includes strategizing in-house drug discovery program, recommend plans and proposals for identification of lead candidates. Member of the Drug Discovery core-group at Wockhardt for assessment of over-all profile of NCE and propose further action on ‘go-no go decision’ and putting forth strategic plans for initiation of new therapeutic areas for the new spin-off company. Also involved in overseeing the quality aspects of biotech products w.r.t. biological efficacy & safety of bulk and formulation for nation & international market release. As a member of the corporate strategic group involved in identifying and proposing a second therapeutic area to enhance research capability portfolio for the new spin-off company.
- Oversee and plan exploratory and regulatory screening of new chemical entities (NCEs) for their safety/toxicity, generate tox structure activity relationship (SAR) for lead optimization, prepare toxicity profile of NCE for decision making, presenting data for in-licensing opportunities and regulatory submission. Predestine strategies in development of novel NCEs to be perceived as a drug candidate for investigational new drug (IND) application. Involved in specific decision making for clinical go-no go of NCEs and extending strategic inputs for identification of a new therapeutic area, addressing issues w.r.t. market trends. Proposing appropriate infrastructural needs and specifying road-maps for rationalization of new therapeutic research based on market trends. Generate safety data for Biotech products and monitor the quality control procedures by conducting pharmacopeial studies for batch and formulation release. Strategic assistance extended to veterinary division for generating animal bioequivalence study data for veterinary products.
- Responsibilities :-
- Have successfully conceptualized; designed and upgraded the facility to a fully functional state-of-the-art preclinical safety assessment division including an in vitro toxicology laboratory for preliminary screening of NCEs.
- Identifications of equipments and interactions with biomedical instrument companies and propose purchase sophisticated instruments/equipments for clinical pathology, necropsy, histopathology, kinetic analysis, data processing and documentation, hardware’s and soft-wares for data compilation, statistics, image transfer and maintenance of animal house records (animal records, air conditioning/ventilation, lighting,) metabolic cages, cages as per international specification, humidity and temperature recorders and data-logging systems.
- Planning and preparation of annual capital and revenue budget for preclinical safety assessment division and animal house along with man power requirements. new project proposals for new product launches is also suggested as per market trend and to strengthen company’s brand profile.
- Selection of a core team of scientists and technicians for toxicology, QC screening of biotech products and animal-house. Formation of team included screening of various candidates and identifying personnel specific for various activities in toxicology, toxicokinetics, biotechnology and animal-house. Imparting training in various aspects of toxicity studies including procedural and different methods to scientists, junior scientists and other staff members. Presently, heading a team of 18 scientists and research associates in toxicology, kinetics, bioefficacy and animal house division.
- Identified and prepared, edited and authorized standard operating procedures (SOPs) and organized proper quality system in the functional laboratory for core and critical functional areas in the preclinical safety assessment division and biotech QC.
- Have designed and devised a new phototoxicity model to determine phototoxic potential of NCEs in mice. (first of its kind in India). Have also developed a model to identify NCEs with potential for bone marrow suppression and chondrotoxicity. Standardized methods for telemetry studies in dogs.
- As a principal toxicologist and investigator, have planned protocols and executed toxicity studies along with kinetics which included acute, subchronic, phototoxicity, mutagenicity (in vitro & in vivo), teratogenicity studies, preliminary Beagle dog repeated dose studies and short term study models for determining myelosupression, chondrotoxicity and CNS effects. All toxicity data generated on NCEs compiled and profiles prepared for lead optimization and decision making to envisage potential investigational new drug (IND) candidate. Till date more than 3000 NCEs have been screened which includes NCEs from fluoroquinolones, oxazolodinones and macrolide/ketolides class of antibacterials. 7 lead molecules have been identified based on acceptable efficacy/safety profile (therapeutic index). Presently 4 molecules are in the advanced stage of preclinical studies.
- Have standardized quality control screening models for assessment of bioefficacy, bioidentity & abnormal toxicity as per European & Indian Pharmacopeia for screening of erythropoietin & insulin API & formulation for market release of batches.
- Had prepared green files for 5 NCEs and IND document for an systemic and an oral anti-infective molecule. India’s first antiinfective IND for WCK 771 was filed in November 2001 & permission for phase 1 clinical studies was granted in march 2002. Two more INDs on a NCE against respiratory tract infection (oral & i.v.) was filed in December 2003 & for a anti-MRSA oral NCE in Sept 2007. Was an active member involved in editing and auditing preclinical dossiers for successfully filing Wockhardt’s and India’s first antibacterial Investigational New Drug (IND) application with the US-FDA for 2 NCEs and have obtained permission to conduct phase-1 clinical trials in the USA.
- Correspondence & interaction with international contract research organizations (CRO) for conduct of exploratory and GLP pharmacokinetic, pharmacology and toxicity studies. Have developed extensive networking amongst top CROs such as Huntingdon Life Sciences. UK; Southern Research Center, USA; Toxikon, USA; RCC, Swiss; and Biotest Limited, Czech Republic. Interactions includes correspondence, evolving outline protocols, final protocol approvals, study agreements, negotiating prices, study authorization, on-site study monitoring, draft and final report auditing and acceptance of the same.
- Planning of protocols, dosages and conduct of animal kinetics studies, acute and sub-chronic toxicity studies on known drugs (generics) developed by optimized process (process patent), new drug formulation developed through NDDS route for marketing permission in India and US. Execution and generation of dog bioequivalence data for various veterinary products. Member of the due-diligence team for assessment of pre-clinical profile of data-base for in-licensing of products or company take-over.
- Member of the company’s Core Group for decision making from the preclinical efficacy and safety aspects for generic and biotechnological products for introducing products in national and international (US & Europe) market.
- Monitor various aspects of regular quality upgradation of the department to ensure implementation of Good Laboratory Practices during the study period, plan yearly budgetary requirements (capital and revenue) and identify deficient areas and take appropriate corrective actions to overcome the same.
- Well versed with the regulatory requirements and guidelines for toxicology screening of NCEs for US-FDA, EEC (EMEA), OECD & DCGI IND & NDA filing.
- Have conceptually designed and planned a new Beagle dog facility for kinetics and safety studies in NCEs. The plan has been finalized. the facility has been established and is fully functional. the facility presently holds 97 Beagle dogs.
- Have designed and planned a AALAC approvable new animal house and GLP testing facility for Wockhardt’s Drug Discovery and biotechnology program for carrying out efficacy and toxicology studies on NCEs and biotechnological products for national and international market. The plan has been finalized and construction for the same is under-way.
- Was actively involved in the formation of a 7-member Wockhardt animal ethics committee to institutionalize and monitor the indiscriminate use of animals and regulate/monitor the functioning of animal-house activity.
In appreciation of my performance, I was honored with the ‘Significant Performance Award’ for the year 2000 and 2003.
Was promoted from Chief Scientist (DGM) to Chief Scientist (GM) in 2002, from Chief Scientist to Associate Director in 2006 and to Sr. Associate Director in 2008.
Resigned in March 2009.
1994- 1998
- Joined the New Drug Discovery Research (NDDR) division of Ranbaxy Laboratories Limited, New Delhi in october 1994 as a Research Scientist – Toxicologist.
Achievements :
- Designed and established a fully functional toxicology division at R & D centre Okhla, New Delhi.
- Planned and procured sophisticated instruments for various functions in toxicology laboratory.
- Identification of core and critical areas in toxicology labs. and preparation, edition and authorization of standard operating procedures (SOP) and implementation of proper quality system in all functional laboratories.
- Imparting training in various aspects and phases in toxicology including procedural/differential methods viz. dosing, dose formulation, handling of animals, clinical observation, recording, compilation of data, study execution, blood collection, euthanasia, tissue collection, clinical pathology, histopathology, statistics etc. to scientists, junior scientists and other staff personnel. Management and control of all phases of studies for quality adherence.
- Co-ordination with national/international regulatory authorities to procure guidelines, procedures, norms and requirements for investigational new drug application (IND) and new drug application (NDA) of new chemical entities (NCEs).
- Planning, preparation of protocols and execution of all short and long term toxicity studies on NCEs as a study director. Generated toxicity data and prepared toxicity profiles of NCEs from various therapeutic areas which included 13 anticancer, 8 antihypertensive, 3 BPH, 115 anti-infective and 2 cardiovascular agents. Have planned and put-forth a complete conceptual strategy including costing for IND-directed studies for a promising BPH molecule which has been perceived for clinical studies. Involved in execution of efficacy studies in nude mice model to assess anticancer potential of NCEs.
- Was the principal investigator for all toxicity studies conducted on BPH molecule for filing india’s first investigational new drug application (IND) with DCGI. the studies included; acute studies in mice and rats, lethality study in mongrel and Beagle dogs, 28 and 90 days subchronic study in rats, 28 day subacute study in beagle dogs, toxicokinetics in rats and dogs and mutagenicity studies. Complete toxicity reports and profiles of the new BPH compound was generated, compiled and edited for IND submission which was granted and presently phase II clinical trials are on.
- Planned a state of the art new toxicology facility and animal house. The plan has been approved and the facility has been established as per the proposed plan at Gurgaon, Haryana. The facility has been planned to comply with international standards of good laboratory practices (GLP) and all studies will conform to requirements of US-FDA and European regulations.
- Have led a group of scientists to standardize in-vitro techniques for toxicity screening and establishing a genetic toxicology laboratory at nddr. as a group-leader representing the toxicology section at the Ranbaxy’s n-forum have put forth new ideas/approaches for drug discovery processes and quality management.
- Imparted training in toxicology and GLP concepts to 3 post graduate summer trainee students various industries.
- Have planned and designed a complete animal–house & animal experimental unit for a new facility at Gurgoan. have also planned and designed a beagle dog facility at Chatturpur, New Delhi for carrying out in-house toxicity and pharmacology studies on NCE’s.
- Have prepared and submitted complete conceptual plans and design for setting up of a GLP “National Facility for Regulatory Toxicology and Animal House for rodents, Beagle dogs and other non-rodents”. This was pursued as a national contract research organization managed as a joint-venture between Council of Scientific and Industrial Research (CSIR) and industry to offer services for conducting studies on new drugs and chemicals acceptable to national and international regulatory authorities. This proposal has been submitted to the governing council of CSIR and industry and some major companies has been invited for collaboration. The planning for this project includes strategic operational details, designing of infrastructure, identifying equipments, total budgeting (building, capital, revenue and recurring costs), pricing and manpower requirements.
In view of my performance I was promoted to the next higher grade as a Sr. Scientist in 1998. I resigned Ranbaxy Ltd in March 1998.
1992- 1994
- Joined Jai Research Foundation (JRF), Vapi, Gujarat, India in August 1992 as a Research Officer. Jai Research Foundation is a contract laboratory (CRO) and a sister concern of United Phosphorus Limited. JRF is a registered organization under societies registration act xxi, 1860, recognized by Department of Science and Technology. Immediate goal was to write and edit quality manual for obtaining certification and approvals from National Co-ordination of Testing and Calibration Ffacilities (NCTCF) and National Accreditation Board for Testing and Calibration Laboratory (nabl), Government of India. JRF received subsequent certifications on December 1992 from NCTCF and on January 1994 from NABL.
- At JRF, I was given independent task to establish and successfully developed a well equipped toxicology unit and animal house for safety evaluation of drugs, pesticides, agro-chemicals and drug intermediates. Toxicity data was generated for various clients/sponsors as per agreed protocols in accordance with Indian and international regulatory guidelines for marketing permission.
- Was in-charge, as a study director, for numerous toxicity projects which included acute, primary skin irritation, skin sensitization, eye irritation, mucous membrane, sub-acute, sub-chronic, chronic, teratogenicity, fertility, pre and post natal, 2-generation reproductive, in vitro chromosomal aberration and human lymphocyte, in vivo micronucleus and rat/mouse chromosomal aberration, carcinogenicity, fish toxicity (eco toxicity) and abnormal toxicity studies on different classes of drugs, pesticides, agrochemical, effluents and drug intermediates. I had standardized methods for in vitro human lymphocytes and teratogenicity studies. My responsibility also included preparation of SOPs, protocols, study plans/schedules, organizing raw data sheets, statistics, interpretation and data curation, evaluation of final results, preparation and submission of final reports to QAU and to sponsors. these reports were subsequently submitted to central insecticide board (CIB), drugs controller general of India (DCGI), environment protection agency (EPA) USA and to regulatory agencies in Japan, China, Taiwan, Singapore, Malaysia and some OECD countries.
Was promoted in 1994 and upgraded as a Senior Research Officer and was made in-charge, Toxicology.
1986 - 1992
- Initiated professional career from 1986 as a Research Assistant in the toxicology unit of Ruia Analytical Laboratory, Bombay, an FDA (Maharashtra, India) approved laboratory for safety evaluation of chemicals, drugs and cosmetics.
- Responsibilities included, safety evaluation and toxicity testing of various drugs and cosmetics from reputed pharmaceutical companies, compilation of data, preparation of final reports and submission for approvals. the approved final reports were submitted to FDA-Maharashtra or Drugs Controller General of India (DCGI) for marketing permission in India.
- Was project in-charge/study director for various acute, sub-acute, sub-chronic, fertility, teratogenicity, in vivo micronucleus and abnormal toxicity studies. i was also involved in pyrogen testing, vasopressin activity (oxytocin), skin sensitization, primary skin irritation and eye irritation studies. these studies were a prerequisite for marketing permission of drugs and cosmetics. I was also involved in the maintenance of the animal house at Ruia Analytical Laboratory.
For my performance I was first promoted as a Junior Research Scientist and then as a Research Scientist.

Signature : …………-sd/.-….………………… Date : September 2009
(Dr. Nitin Shetty, K. M.)

Additional Information
1. Industry Preference :- Pharmaceutical (Drug Discovery Research) or
Contract Research Organization
2. Location Constraints :- None
3. DOB : July 13, 1964
4. Present Designation :- Vice President – Preclinical Division
Vimta Labs Limited, Hyderabad, AP
4. Present Package : - Rs. 72.8 lakhs p.a. (+ resi. phone, credit card,
mobile – rentals & official calls, petro card)
5. Expected Package :- Approx 20-30% of present CTC
6. Joining Time Required :- 3 months following receipt of appointment letter

9. Physical Defects : None
10. Reason for Change : To take up broader responsibilities

-------------------------------------------------------
More Information about this submission and submitter:-
___________________________________________________
Submission ID : 4381406
Date & Time : 17th Jul 2011 6:37 PM (UTC)
IP Address : 117.200.164.26
Browser Info : Mozilla/5.0 (Windows NT 6.1) AppleWebKit/534.30 (KHTML, like Gecko) Chrome/12.0.742.122 Safari/534.30
Predicted Country : India